drugset / Trial / NCT01347983
Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
24 week open-labeled extension study to continue monitoring the same group of patients in the previous MRA230TW phase IIIb trial in order to evaluate the long term efficacy and safety of tocilizumab.
Timeline
- Start
- 2011-05
- Primary completion
- 2013-03
- Completion
- 2013-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |
| Background | Methotrexate | Small molecule | 10 mg | — |
| Background | Methotrexate | Small molecule | 20 mg | — |